ALK expands partnership with Abbott
Denmark’s ALK has expanded its partnership with US-based group Abbott concerning its allergy pill Acarizax on seven South-East Asian growth markets. Abbott will return some of the commercial rights later on, ALK’s CFO tells MedWatch.
BY LOUISE WENDT JENSEN & LONNI LYNGE
ALK’s oral treatment against house dust mite allergy, Acarizax, is headed to seven growth markets in South-East Asia in the near future, the company says in a market wire Thursday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK races against the clock on price approval
For abonnenter
ALK: We have to reach out to doctors now
For abonnenter
